Blood pressure control, drug therapy, and kidney disease

Hypertension

Volumn 46, Issue 1, 2005, Pages 44-50

  Contreras, Gabriel ^a,m   Greene, Tom ^b   Agodoa, Lawrence Y ^c   Cheek, DeAnna ^d   Junco, George ^a   Dowie, Donna ^e   Lash, James ^f   Lipkowitz, Michael ^g   Miller III, Edgar R ^h   Ojo, Akinlou ⁱ   Sika, Mohammed ^j   Wilkening, Beth ^k   Toto, Robert D ^l  

^a UNIVERSITY OF MIAMI   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e HARLEM HOSPITAL CENTER   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g MOUNT SINAI HOSPITAL   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k EMORY UNIVERSITY   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m RMSB   (United States)

more..

Author keywords

Angiotensin converting enzyme; Calcium channel blockers; Hypertension; Renal disease

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MINOXIDIL; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DEATH; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AFRICAN AMERICANS; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; METOPROLOL; MIDDLE AGED; PROTEINURIA; RAMIPRIL; TREATMENT OUTCOME;

EID: 21744448809     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000166746.04472.60     Document Type: Article

References (23)

1. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
2. Wright JT Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. African Am Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
3. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:1849-1860.
4. Ruggenenti P, Perna A, Benini R, Remuzzi G for the "gruppo italiano di studi epidemiologici in nefrologia" (GISEN). Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol. 1998;9:2096-2101.
5. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials. A systematic review. JAMA. 2003;289:2545-2553.
6. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NlDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
7. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med. 1994;154:1185-1202.
8. De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino MV. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol. 1993;22:208-214.
9. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
10. Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol. 1985;249:F619-F629.
11. Bidani AK, Schwanz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol. 1987;252: F1003-F1010.
12. Pelayo JC, Westoo JY. Impaired autoregulation of glomerular capillary hydrostatic pressure in the remnant nephron. J Clin Invest. 1991;88:101-105.
13. Bidani AK, Griffin KA, Bakris GL, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000;57:1651-1661.
14. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993-2000.
15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
17. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
18. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Grupo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857-1863.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
20. Parving HH, Lehnen H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. N Engl J Med. 2001;345:870-878.
21. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
22. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-Am and white men: 16-year MR-FIT findings. JAMA. 1997;277:1293-1298.
23. US Renal Data System. USRDS 1999 Annual Data Report. Bethesda. MD: National Institutes of Health. National Institute of Diabetes, Digestive, and Kidney Diseases; 1999.